JP2017503842A5 - - Google Patents

Download PDF

Info

Publication number
JP2017503842A5
JP2017503842A5 JP2016548172A JP2016548172A JP2017503842A5 JP 2017503842 A5 JP2017503842 A5 JP 2017503842A5 JP 2016548172 A JP2016548172 A JP 2016548172A JP 2016548172 A JP2016548172 A JP 2016548172A JP 2017503842 A5 JP2017503842 A5 JP 2017503842A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cell lymphoma
therapeutic agent
hodgkin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016548172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503842A (ja
JP6855243B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/012733 external-priority patent/WO2015112888A1/en
Publication of JP2017503842A publication Critical patent/JP2017503842A/ja
Publication of JP2017503842A5 publication Critical patent/JP2017503842A5/ja
Application granted granted Critical
Publication of JP6855243B2 publication Critical patent/JP6855243B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016548172A 2014-01-24 2015-01-23 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 Expired - Fee Related JP6855243B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461931075P 2014-01-24 2014-01-24
US201461931078P 2014-01-24 2014-01-24
US61/931,075 2014-01-24
US61/931,078 2014-01-24
US201462077127P 2014-11-07 2014-11-07
US62/077,127 2014-11-07
PCT/US2015/012733 WO2015112888A1 (en) 2014-01-24 2015-01-23 Apilimod compositions and methods for using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020201440A Division JP2021046430A (ja) 2014-01-24 2020-12-04 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物

Publications (3)

Publication Number Publication Date
JP2017503842A JP2017503842A (ja) 2017-02-02
JP2017503842A5 true JP2017503842A5 (cg-RX-API-DMAC7.html) 2018-03-08
JP6855243B2 JP6855243B2 (ja) 2021-04-07

Family

ID=53681989

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016548172A Expired - Fee Related JP6855243B2 (ja) 2014-01-24 2015-01-23 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
JP2020201440A Pending JP2021046430A (ja) 2014-01-24 2020-12-04 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020201440A Pending JP2021046430A (ja) 2014-01-24 2020-12-04 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物

Country Status (12)

Country Link
US (3) US10179135B2 (cg-RX-API-DMAC7.html)
EP (1) EP3096757B1 (cg-RX-API-DMAC7.html)
JP (2) JP6855243B2 (cg-RX-API-DMAC7.html)
KR (1) KR102320190B1 (cg-RX-API-DMAC7.html)
CN (1) CN106659716B (cg-RX-API-DMAC7.html)
AU (1) AU2015209133B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016017112A2 (cg-RX-API-DMAC7.html)
CA (1) CA2937655C (cg-RX-API-DMAC7.html)
IL (1) IL246879B (cg-RX-API-DMAC7.html)
MX (1) MX373818B (cg-RX-API-DMAC7.html)
RU (2) RU2016134406A (cg-RX-API-DMAC7.html)
WO (1) WO2015112888A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6855243B2 (ja) 2014-01-24 2021-04-07 エイアイ・セラピューティクス・インコーポレーテッド 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
CN107427522B (zh) * 2014-11-07 2021-06-15 人工智能治疗公司 用于治疗黑素瘤的阿吡莫德
EP3215158B1 (en) 2014-11-07 2019-05-08 AI Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
US10729694B2 (en) 2015-01-23 2020-08-04 AI Therapeutics, Inc. Anti-viral compositions containing PIKfyve inhibitors and use thereof
US20180078561A1 (en) * 2015-03-31 2018-03-22 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
US20190015421A1 (en) * 2016-01-21 2019-01-17 Lam Therapeutics, Inc. Biomarkers for Treating Cancer with Apilimod
KR20180015441A (ko) 2016-08-03 2018-02-13 엘지전자 주식회사 롤리 키보드
CN109952113A (zh) * 2016-08-25 2019-06-28 人工智能治疗公司 包含pikfyve抑制剂的组合物和与rank信号传导的抑制相关的方法
WO2019164861A1 (en) * 2018-02-21 2019-08-29 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物
CN110496128B (zh) * 2019-09-23 2022-09-30 吉林大学 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用
EP4090426B1 (en) 2020-01-13 2025-12-31 Verge Analytics, Inc. Substitutes for pyrazolos and pyrimidines and their uses
BR112023025552A2 (pt) * 2021-06-11 2024-02-27 Orphai Therapeutics Inc Composições estabilizadas de apilimod e usos das mesmas

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
DE69435060T2 (de) 1993-11-12 2009-01-02 Phri Properties, Inc. Hybridisierungsprobe zur nukleinsäuredetektion, universelle stammstrukturen, methoden und reagentiensätze
US6693097B2 (en) 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
JP4996261B2 (ja) 2004-02-06 2012-08-08 エラン ファーマシューティカルズ，インコーポレイテッド 腫瘍および転移性疾患を処置するための方法および組成物
AU2005244745B2 (en) 2004-04-13 2012-05-03 Synta Pharmaceuticals Corp. Disalt inhibitors of IL-12 production
JP2008512490A (ja) * 2004-09-08 2008-04-24 チェルシー・セラピューティクス，インコーポレイテッド 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
WO2006053112A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Process for preparing trisubstituted pyrimidine compounds
WO2006124662A1 (en) 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US7700594B2 (en) 2005-11-17 2010-04-20 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007087395A2 (en) 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
DK2038252T3 (en) 2006-07-12 2016-12-19 Univ Tennessee Res Found SUBSTITUTED AND ACYLANILIDER methods of use thereof
KR20090108124A (ko) 2007-02-06 2009-10-14 노파르티스 아게 Ｐｉ 3-키나제 억제제 및 그의 사용 방법
RU2438664C2 (ru) 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5258331B2 (ja) * 2008-03-03 2013-08-07 ロート製薬株式会社 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2544674B1 (en) 2010-03-08 2017-10-25 Sloan Kettering Institute For Cancer Research Cdc7 kinase inhibitors and uses thereof
ES2768349T3 (es) 2010-03-29 2020-06-22 Ea Pharma Co Ltd Preparación farmacéutica que comprende un derivado de fenilalanina
US8402515B2 (en) 2010-05-06 2013-03-19 Jonathan Weizman Apparatus and method for establishing a peer-to-peer communication session with a client device
US20110287018A1 (en) * 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
HUE040152T2 (hu) * 2010-11-19 2019-02-28 Ecole Polytechnique Fed Lausanne Epfl 2-Piperazin-l-il-4H-l,3-benzotiazin-4-on származékok és alkalmazásuk emlõsöket érintõ fertõzések kezelésében
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US20140105891A1 (en) 2012-10-05 2014-04-17 Cerulean Pharma Inc. Treatment of cancer
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
JP6855243B2 (ja) 2014-01-24 2021-04-07 エイアイ・セラピューティクス・インコーポレーテッド 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
CN107427522B (zh) 2014-11-07 2021-06-15 人工智能治疗公司 用于治疗黑素瘤的阿吡莫德
EP3215158B1 (en) 2014-11-07 2019-05-08 AI Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
US20180015098A1 (en) 2015-02-03 2018-01-18 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
US20180078561A1 (en) 2015-03-31 2018-03-22 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
AU2019299234A1 (en) 2018-07-05 2021-01-14 Mayo Foundation For Medical Education And Research PIKfyve inhibitors
AR119934A1 (es) 2019-09-12 2022-01-19 Ai Therapeutics Inc Inhibidores de pikfyve para terapia contra el cáncer

Similar Documents

Publication Publication Date Title
JP2017503842A5 (cg-RX-API-DMAC7.html)
RU2019107011A (ru) Композиции апилимода и способы их применения
EP2562177A3 (en) Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
NZ604040A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2009001359A3 (en) Compositions and methods for inhibiting expression of pro-apoptotic genes
JP2016513097A5 (cg-RX-API-DMAC7.html)
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
SI2324008T1 (sl) 3,4-diarilpirazoli kot protein-kinazni inhibitorji
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
MX336710B (es) Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades.
EA201201403A1 (ru) Очень низкодозированные твердые пероральные лекарственные формы для гзт
JP2020505433A5 (cg-RX-API-DMAC7.html)
MX2024012131A (es) Composicion farmaceutica, uso de la misma y metodo para tratar el cancer
WO2015034678A3 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
JP2016539156A5 (cg-RX-API-DMAC7.html)
WO2018102687A3 (en) Combination therapy for treating cancer
JP2016529285A5 (cg-RX-API-DMAC7.html)
JP2018090566A5 (cg-RX-API-DMAC7.html)
PH12018502422A1 (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
JP2016515586A5 (cg-RX-API-DMAC7.html)
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
JP2017516802A5 (cg-RX-API-DMAC7.html)
WO2017042633A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
JP2018503610A5 (cg-RX-API-DMAC7.html)